To effectively target sortilin and syndecan-1 on the cell surface of prostate cancer cells, specific anti-sortilin and anti-syndecan-1 monoclonal antibodies were generated against extracellular domains of these integral membrane proteins. Here, SORT1 is linked to prostate carcinoma.